[woodmqf译] 双相情感障碍——共病及杂项篇

其他疾病会与双相情感障碍共病吗？

在双相人群中，酒精和药物滥用是非常普遍的。研究发现表明许多因素可能造成这些物质滥用问题，包括症状的自我医疗，物质滥用导致的情绪症状的发作或持续以及可能影响双相情感障碍和物质使用障碍发生的风险因素。如果共病的物质滥用存在，那么，它将是整个治疗计划的重要一环。

焦虑障碍，诸如，创伤后应激障碍和强迫症也在双相人群中很普遍。共病的焦虑障碍可能会因双相情感障碍的治疗而解除，或者它们可能需要分开治疗。

更多信息：

参见the National Library of Medicine's MedlinePlus and En Español

关于临床试验的信息：

NIMH supported clinical trials

National Library of Medicine Clinical Trials Database

来自NIMH的信息可以以多种形式使用。你可以在线浏览，下载PDF文档，通过邮件订阅纸质小册子。如果你想要NIMH的出版物，你可以在线订阅它们www.nimh.nih.gov。如果你没有因特网服务，但希望得到出版物增补的信息，清联系NIMH信息中心，下方是各种号码：

国家精神健康研究院（NIMH）

Science Writing, Press & Dissemination Branch

6001 Executive Boulevard

Room 8184, MSC 9663

Bethesda, MD 20892-9663

电话: 301-443-4513 或

1-866-615-NIMH (6464) 接方付费

电传: 301-443-8431

电传: 866-415-8051

传真: 301-443-4279

邮箱nimhinfo@nih.gov

网址: http://www.nimh.nih.gov

参考书目：

1. Kessler RC, Chiu WT, Demler O, Walters EE. Prevalence, severity, and comorbidity of twelve-month DSM-IV disorders in the National Comorbidity Survey Replication (NCS-R). Archives of General Psychiatry, 2005 Jun;62(6):617-27.

2. American Psychiatric Association. Diagnostic and Statistical Manual for Mental Disorders, fourth edition (DSM-IV).Washington, DC: American Psychiatric Press, 1994.

3. Hyman SE, Rudorfer MV. Depressive and bipolar mood disorders. In: Dale DC, Federman DD, eds. Scientific American. Medicine. Vol. 3.New York: Healtheon/WebMD Corp., 2000; Sect. 13, Subsect. II, p. 1.

4. Goodwin FK, Jamison KR. Manic-depressive illness.New York: Oxford University Press, 1990.

5. Geller B, Luby J. Child and adolescent bipolar disorder: a review of the past 10 years. Journal of the American Academy of Child and Adolescent Psychiatry, 1997; 36(9): 1168-76.

6. NIMH Genetics Workgroup. Genetics and mental disorders.NIH Publication No. 98-4268. Rockville, MD: National Institute of Mental Health, 1998.

7. Hyman SE. Introduction to the complex genetics of mental disorders. Biological Psychiatry,1999; 45(5): 518-21.

8. Soares JC, Mann JJ. The anatomy of mood disorders—review of structural neuroimaging studies. Biological Psychiatry, 1997; 41(1): 86-106.

9. Soares JC, Mann JJ. The functional neuroanatomy of mood disorders. Journal of Psychiatric Research,1997; 31(4): 393-432.

10. Sachs GS, Printz DJ, Kahn DA, Carpenter D, Docherty JP. The expert consensus guideline series: medication treatment of bipolar disorder 2000. Postgraduate Medicine,2000; Spec No:1-104.

11. Sachs GS, Thase ME. Bipolar disorder therapeutics: maintenance treatment. Biological Psychiatry,2000; 48(6): 573-81.

12. Huxley NA, Parikh SV, Baldessarini RJ. Effectiveness of psychosocial treatments in bipolar disorder: state of the evidence. Harvard Review of Psychiatry,2000; 8(3): 126-40.

13. Vainionpaa LK, Rattya J, Knip M, Tapanainen JS, Pakarinen AJ, Lanning P, Tekay A, Myllyla VV, Isojarvi JI. Valproate-induced hyperandrogenism during pubertal maturation in girls with epilepsy. Annals of Neurology, 1999; 45(4): 444-50.

14. Llewellyn A, Stowe ZN, Strader JR Jr. The use of lithium and management of women with bipolar disorder during pregnancy and lactation. Journal of Clinical Psychiatry,1998; 59(Suppl 6): 57-64; discussion 65.

15. Thase ME, Sachs GS. Bipolar depression: pharmacotherapy and related therapeutic strategies. Biological Psychiatry, 2000; 48(6): 558-72.

16. Suppes T, Webb A, Paul B, Carmody T, Kraemer H, Rush AJ. Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. American Journal of Psychiatry,1999; 156(8): 1164-9.

17. Tohen M, Sanger TM, McElroy SL, Tollefson GD, Chengappa KN, Daniel DG, Petty F, Centorrino F, Wang R, Grundy SL, Greaney MG, Jacobs TG, David SR, Toma V. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. American Journal of Psychiatry,1999; 156(5): 702-9.

18. Rothschild AJ, Bates KS, Boehringer KL, Syed A. Olanzapine response in psychotic depression. Journal of Clinical Psychiatry,1999; 60(2): 116-8.

19. U.S. Department of Health and Human Services. Mental health: a report of the Surgeon General.Rockville, MD: U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Mental Health Services, National Institutes of Health, National Institute of Mental Health, 1999.

20. Henney JE. Risk of drug interactions with St. John’s wort. From the Food and Drug Administration. Journal of the American Medical Association,2000; 283(13): 1679.

21. Nierenberg AA, Burt T, Matthews J, Weiss AP. Mania associated with St. John’s wort. Biological Psychiatry,1999; 46(12): 1707-8.

22. Stoll AL, Severus WE, Freeman MP, Rueter S, Zboyan HA, Diamond E, Cress KK, Marangell LB. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Archives of General Psychiatry,1999; 56(5): 407-12.

23. Strakowski SM, DelBello MP. The co-occurrence of bipolar and substance use disorders. Clinical Psychology Review,2000; 20(2): 191-206.

24. Mueser KT, Goodman LB, Trumbetta SL, Rosenberg SD, Osher FC, Vidaver R, Auciello P, Foy DW. Trauma and posttraumatic stress disorder in severe mental illness. Journal of Consulting and Clinical Psychology,1998; 66(3): 493-9.

25. Strakowski SM, Sax KW, McElroy SL, Keck PE Jr, Hawkins JM, West SA. Course of psychiatric and substance abuse syndromes co-occurring with bipolar disorder after a first psychiatric hospitalization. Journal of Clinical Psychiatry,1998; 59(9): 465-71.

阳光工程心理互助公益网